Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma

BackgroundPulmonary metastasectomy (PM) for metastatic sarcoma can result in long-term survival. The purpose of this study was to describe factors associated with survival in a series of patients undergoing PM for metastatic sarcoma. MethodsWe reviewed all patients undergoing PM for metastatic sarcoma over a 12-year period (2000-2012). Multivariate analyses were used to identify factors associated with outcomes. Survival was calculated with Kaplan-Meier and Cox proportional hazard models. ResultsA total of 120 patients underwent PM with a median follow-up was 48 months. Among 81 (85%) patients who presented with local disease, the median disease free interval (DFI) was 13 months and median overall survival (OS) was 48 months. Fourteen patients (15%) had synchronous metastasis with a median OS of 21 months. On multivariate analysis, synchronous metastasis (P=0.005), older age (P=0.02), and number of lung lesions (P=0.003) were associated with poor survival. The median OS of patients with a DFI 12 versus <12 months following primary resection was 93 and 43 months (P=0.004). ConclusionWhile patients with a DFI >12 months have the best OS following PM, patients with a DFI <12 months also have excellent outcomes as compared to systemic therapy and should be considered for PM. J. Surg. Oncol. 2015 111:103-106. (c) 2015 Wiley Periodicals, Inc.